Program
drotokibart
Also written as “SHR-1819 Injection” and “SHR-1819 injection”.
In Jiangsu HengRui Medicine's pipeline, IL-4Rα
. Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Prurigo, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Aug 5, 20248 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 84 open or running | phase 3since Aug 5, 2024 | Aug 22, 2023 | Dec 2026phase 3 · NCT07688772 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2023First study: phase 2 study in Moderate to Severe Atopic DermatitisFirst studyNCT06012812 · 79 enrolled · China
- Aug 5, 2024Phase 3 study in Prurigo NodularisNCT06554509 · 423 planned · China
- Nov 24, 2024Phase 2 study in Children and Adolescents With Moderate-to-severe Atopic DermatitisNCT06713499 · 51 enrolled · China
- Jul 21, 2025Phase 2 study in Rhinitis, Allergic, SeasonalNCT07091357 · 108 enrolled · China
- Nov 24, 2025Phase 1 study in Dermatitis, AtopicNCT07264335 · 160 enrolled · China
- Dec 15, 2025Phase 3 study in Adolescents With Moderate-to-severe Atopic DermatitisNCT07309055 · 201 planned · China
- Dec 21, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951 · 201 enrolled · China
- Jun 26, 2026Phase 3 study in Rhinitis, Allergic, SeasonalNCT07688772 · 220 enrolled · China
Ahead
- Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalNCT07688772
- Jun 2027Primary completion: phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951
- Nov 2027Primary completion: phase 3 study in Adolescents With Moderate-to-severe Atopic DermatitisNCT07309055
- Oct 2028Primary completion: phase 3 study in Prurigo NodularisNCT06554509
TargetBeta
“IL-4Rα”the company's pipeline, read by Claude · source
Other programs on IL4R
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07688772Rhinitis, Allergic, Seasonal · China | 3 | Active, not recruiting | Dec 2026 | 220 |
| NCT07321951Moderate-to-severe Atopic Dermatitis · China | 2 | Active, not recruiting | Jun 2027 | 201 |
| NCT07309055Adolescents With Moderate-to-severe Atopic Dermatitis · China | 3 | Recruiting | Nov 2027 | 201 |
| NCT07264335Dermatitis, Atopic · China | 1 | Completed | Jun 26, 2026 | 160 |
| NCT07091357Rhinitis, Allergic, Seasonal · China | 2 | Completed | Dec 1, 2025 | 108 |
| NCT06713499Children and Adolescents With Moderate-to-severe Atopic Dermatitis · China | 2 | Completed | Nov 22, 2025 | 51 |
| NCT06554509Prurigo Nodularis · China | 3 | Recruiting | Oct 2028 | 423 |
| NCT06012812Moderate to Severe Atopic Dermatitis · China | 2 | Completed | Jun 5, 2025 | 79 |
How it is read
Names in the registry
- “SHR-1819 Injection”, 6 entries
- “SHR-1819 injection”, 2 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 5 studies
- Rhinitis, Allergic, Seasonal, 2 studies
- Prurigo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.